MECOM
MECOM (Histone-lysine N-methyltransferase MECOM) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Endometrial cancer and 5 more.
Overview
Functions as a transcriptional regulator binding to DNA sequences in the promoter region of target genes and regulating positively or negatively their expression. Oncogene which plays a role in development, cell proliferation and differentiation. May also play a role in apoptosis through regulation of the JNK and TGF-beta signalling.
CIViC holds 5 clinical evidence items and 1 assertion across 3 variants. Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes affected pathway 0.26, literature 0.99, genetic association 0.63, somatic mutation 0.80, animal model 0.50). IntOGen calls it a driver in 6 cohorts (3 activating, 3 loss-of-function), covering Invasive Breast Carcinoma, Melanoma, Prostate Adenocarcinoma, Endometrial Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · MECOM (Histone-lysine N-methyltransferase MECOM) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Endometrial cancer and 5 more.
- 1 · What it is
MECOM (Histone-lysine N-methyltransferase MECOM) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Endometrial cancer and 5 more.
- 2 · What goes wrong in cancer
Functions as a transcriptional regulator binding to DNA sequences in the promoter region of target genes and regulating positively or negatively their expression.
- 3 · How drugs use it
No product in this corpus aims at MECOM yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:3498 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q03112 (protein name, function text, keywords and locations (REST API)); CIViC gene MECOM (5 evidence items, 1 assertions, 3 variants; diseases: Acute Myeloid Leukaemia With MECOM Rearrangement, Acute Myeloid Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000085276 (association with cancer (MONDO_0004992) 0.75; per-cancer scores at or above 0.5: prostate cancer 0.54, ovarian cancer 0.51, melanoma 0.61, skin cancer 0.57, breast cancer 0.59, lung cancer 0.54 (GraphQL API, CC0)); IntOGen MECOM (driver in 6 cohorts (Act 3, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Functions as a transcriptional regulator binding to DNA sequences in the promoter region of target genes and regulating positively or negatively their expression. Oncogene which plays a role in development, cell proliferation and differentiation. May also play a role in apoptosis through regulation of the JNK and TGF-beta signalling. Involved in haematopoiesis. Displays histone methyltransferase activity and monomethylates 'Lys-9' of histone H3 (H3K9me1). Probably catalyses the monomethylation of free histone H3 in the cytoplasm which is then transported to the nucleus and incorporated into nucleosomes where SUV39H methyltransferases use it as a substrate to catalyse histone H3 'Lys-9' trimethylation. Location: Nucleus; Nucleus speckle; Cytoplasm (UniProt). Locus 3q26.2 (HGNC).
- Breast cancer: Open Targets association 0.59 with breast cancer (MONDO_0007254); IntOGen driver in 1 cohort (BRCA)
- Prostate cancer: Open Targets association 0.54 with prostate cancer (MONDO_0008315); IntOGen driver in 1 cohort (PRAD)
- Endometrial cancer: IntOGen driver in 1 cohort (UCEC)
- Skin cancer: Open Targets association 0.57 with skin cancer (MONDO_0002898)
- Lung cancer: Open Targets association 0.54 with lung cancer (MONDO_0008903)
- Ovarian cancer: Open Targets association 0.51 with ovarian cancer (MONDO_0008170)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts; CIViC holds 5 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Acute Myeloid Leukaemia With MECOM Rearrangement.
Latest papers
topQuery for this target: (TITLE:"MECOM" OR ABSTRACT:"MECOM" OR TITLE:"MDS1 and EVI1 complex locus" OR ABSTRACT:"MDS1 and EVI1 complex locus" OR TITLE:"Histone-lysine N-methyltransferase MECOM" OR ABSTRACT:"Histone-lysine N-methyltransferase MECOM" OR TITLE:"MDS1-EVI1" OR ABSTRACT:"MDS1-EVI1" OR TITLE:"PRDM3" OR ABSTRACT:"PRDM3" OR TITLE:"KMT8E" OR ABSTRACT:"KMT8E") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MECOM, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetLZTR1
Shares Lung cancer (all types), Skin cancer (all types), Endometrial cancer, Breast cancer (all types).
- TargetRAD51B
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetABL2
Shares Lung cancer (all types), Skin cancer (all types), Endometrial cancer, Breast cancer (all types).
- TargetCBLB
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetBARD1
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetPIK3CB
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetARHGAP35
Shares Lung cancer (all types), Skin cancer (all types), Endometrial cancer, Breast cancer (all types).
- TargetPTPRB
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.